AKT1 and diffuse large B-cell lymphoma: In addition, IL-6 or IL-17A promoted DLBCL cell growth via the JAK2/STAT3 pathway or by upregulating cyclin D2 via the PI3K/Akt pathway.IL-6 generally binds to membrane IL-6 receptor and gp130, activating the JAK2/STAT3 pathway in target cells [32].